Orasure Technologies, Inc. · NASDAQ:OSUR
Orasure Technologies — Investor Presentation (September 2021)
23 slides from Orasure Technologies's investor presentation, Sep 8, 2021
Slide 1: Investor Presentation August 2021
Investor Presentation August 2021 EXHIBIT 99.1
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause act
Slide 3: OraSure's Mission and Vision
OraSure’s Mission and Vision “Smart science made simple.” OUR MISSION: OUR VISION: “Our mission to do good and help solve the world’s greatest health challenges is what drives us. We are committed to making a difference in the world of individual and public health by enabling access to discovery and
Slide 4: We Play Where Healthcare is Going
We Play Where Healthcare is Going Move to point-of-care home testing Growth of personalized medicine Healthcare consumerism
Slide 5: Key Focus Areas to Drive Shareholder Value
Key Focus Areas to Drive Shareholder Value Expand Global Commercial Capabilities and Reach Drive Higher Growth Through Expanded R&D and M&A Expand Into New Sample Types and New Testing Modalities in Molecular Solutions Capitalize on COVID-19 Testing Opportunity To Fund Future Growth
Slide 6: Our Focused Business Units
Our Focused Business Units Infectious Disease Testing HIV HCV COVID-19 EBOLA and FLU Oral fluid substance abuse testing OraSure Technologies provides accurate, effortless, high-value point-of-care and self-test diagnostic solutions for: DIAGNOSTICS 37% of FY20 product revenue Best-in-class tools and
Slide 7: Diagnostics
Diagnostics
Slide 8: Disease, OraSure Products and Product Differentiation
Disease OraSure Products Product Differentiation U.S./Global Disease Incidence Testing Recommendations Number of Tests in U.S. Each Year (All Methods) Global Testing % of Global Tests (POC) Global Market Growth COVID-19 InteliSwab™ COVID-19 Rapid Test Designed to be one of the simplest tests on the
Slide 9: InteliSwab: Designed to be the Simplest COVID-19 Test on the Market
InteliSwab™: Designed to be the Simplest COVID-19 Test on the Market Authorized by FDA for OTC, Prescription Home Use and Professional Point-of-Care CLIA-Waived use Accuracy comparable to other point-of-care offerings (84% sensitivity / 98% specificity) Convenient sample collection with <1 min. of h
Slide 10: Continued elevated need for simple point-of-care testing
Continued elevated need for simple point-of-care testing; Long-term market as COVID-19 becomes endemic U.S. Testing Data Indication expansion for children 2-15 COVID-19 public health reporting app launch Registrations in international markets accepting U.S. FDA EUA Back to school and back to work pr
Slide 11: Key Growth Drivers for the Diagnostic Business
Key Growth Drivers for the Diagnostic Business OraQuick® HIV OraQuick® HCV Intercept® Oral Fluid Drug Testing System InteliSwab™ FY 2021 federal budget includes $386 million for "Ending the HIV Epidemic,” implementation, up from $267 million in FY2020 OUS testing grew at double digit rate (FY15-FY20
Slide 12: Revenue in Key Diagnostic Testing Categories
Revenue in Key Diagnostic Testing Categories Test Revenue (in mil.) Diagnostic business recovering from COVID-19 pandemic. COVID-19 testing revenue expected to begin to increase in Q321 Recovering From Pandemic & Launching COVID-19 Antigen Test
Slide 13: Molecular Solutions
Molecular Solutions
Slide 14: A Global Leader in Sample Collection & Service Solutions for Multi-omic Customers
A Global Leader in Sample Collection & Service Solutions for Multi-omic Customers Provider of best-in-class, proprietary sample collection systems and services to major academic, clinical, and consumer genomics focused labs END MARKETS GROWING IN MID-TEENS Consumer Genomics Clinical Genomics Direct-
Slide 15: Building a Comprehensive Portfolio of Solutions/Services
Building a Comprehensive Portfolio of Solutions/Services Urine* Blood Gut* Oral* Other Skin* Vaginal* End-to-End Quality in Sampling, Services, & Bioinformatics Optimized Sample High Quality Extract & Process Data Capture & Analysis Actionable results driven by Algorithms Human & Animal Health Sampl
Slide 16: Colli-Pee, New Innovation in Sample Collection; Addressing Global HPV Screening Market
Colli-Pee®*, New Innovation in Sample Collection; Addressing Global HPV Screening Market 95%, 95% CI (0.88-1.01) 97%, 95% CI (0.89-1.05) Relative Sensitivity Statistically Equivalent *Colli-Pee® is a research use only product and has not obtained regulatory approval **Van Keer et al., https://doi.or
Slide 17: Accelerating Expansion Into New Sample Types, Multi-omic Research Areas & Services
Accelerating Expansion Into New Sample Types, Multi-omic Research Areas & Services 2004 2011 2005 2008 2014 2016 600 series 2019 6,000 customers – no single customer now greater than 7% of revenue 100 countries where products are sold 3,000 peer reviewed research publications supporting technologies
Slide 18: All-in-one Solutions for Self-collection of Samples for Molecular COVID-19 Testing
All-in-one Solutions for Self-collection of Samples for Molecular COVID-19 Testing All-in-one, easy, reliable and non-invasive self-collection of high quality RNA ORAcollect®·RNA and OMNIgene®·ORAL have received EUAs, interim authorization from Health Canada, and are CE-IVD marked Eight customers to
Slide 19: Expanding Competitiveness Through Multiple Strategies
Expanding Competitiveness Through Multiple Strategies Expanding intellectual property portfolio through filed patents and technology acquisitions (38 patents filed to date on collection devices) Long-term contracts with major customers providing forward visibility Increased regulatory approvals in c
Slide 20: Building a Leadership Position in High-Growth Microbiome Testing Services Market
Building a Leadership Position in High-Growth Microbiome Testing Services Market Largest provider of microbiome testing services to pharma – >30 biopharma collaborations Increasing use of microbiome testing in applications such as cosmetics, animal health, & consumer testing The microbiome is increa
Slide 21: Strong Core Growth in Molecular Solutions
Strong Core Growth in Molecular Solutions Test Revenue (in mil.) 2Q21 One of Strongest Quarters Ever from Genomics & Microbiome Services
Slide 22: Capital Deployment / Strategic Partnerships
Capital Deployment / Strategic Partnerships Using robust balance sheet to create revenue and shareholder value Evaluating companies/technologies in both diagnostics and molecular solutions $229 million in cash on balance sheet* with no debt Four completed acquisitions 2019-2020 Continue to seek acqu
Slide 23: Summary
Summary Commercially tied to high growth areas of healthcare such as consumer/clinical genomics and shift to direct-to-patient/near patient testing Increased investment in internal R&D pipeline and reinvigorating innovation Significant opportunity with COVID-19 testing solutions to drive growth and
OraSure Technologies — Investor Presentation (September 2021) on 6ix